[{"id":"56bb338a-9a55-47ed-87d8-9a54d97136da","acronym":"","url":"https://clinicaltrials.gov/study/NCT03595124","created_at":"2021-01-18T17:40:40.562Z","updated_at":"2025-02-25T16:31:25.872Z","phase":"Phase 2","brief_title":"A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)","source_id_and_acronym":"NCT03595124","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • PD-1 • CD38 • PTPRC • CD69 • TFE3 • CD14 • CD24 • ITGAM • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • CD38 • PTPRC • CD69 • TFE3 • CD14 • CD24 • ITGAM • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • axitinib • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/08/2019","start_date":" 01/08/2019","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 01/23/2026","study_completion_date":" 01/23/2026","last_update_posted":"2025-02-07"},{"id":"c3dd8861-4aa9-4ae4-8df6-b8db6a7c3425","acronym":"","url":"https://clinicaltrials.gov/study/NCT06605664","created_at":"2025-02-26T14:54:29.018Z","updated_at":"2025-02-26T14:54:29.018Z","phase":"Phase 2","brief_title":"Hyperpolarized 13C-MRI in Patients with Hepatocellular Carcinoma Undergoing Radiotherapy, Atezolizumab, and Bevacizumab","source_id_and_acronym":"NCT06605664","lead_sponsor":"Chang Gung Memorial Hospital","biomarkers":" ITGAM","pipe":"","alterations":" ","tags":["ITGAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/30/2024","start_date":" 09/30/2024","primary_txt":" Primary completion: 06/30/2029","primary_completion_date":" 06/30/2029","study_txt":" Completion: 09/30/2031","study_completion_date":" 09/30/2031","last_update_posted":"2024-09-24"},{"id":"114d9c89-e0e5-473e-a324-f2022f9b4244","acronym":"","url":"https://clinicaltrials.gov/study/NCT04465643","created_at":"2021-01-18T21:27:49.677Z","updated_at":"2025-02-25T14:29:26.270Z","phase":"Phase 1","brief_title":"Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor","source_id_and_acronym":"NCT04465643","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PD-L1 • CD20 • CD8 • PD-1 • LAG3 • CD276 • CTLA4 • PD-L2 • VTCN1 • HAVCR2 • IL2RA • CD163 • TIGIT • PTPRC • NCAM1 • ICOS • CD14 • CD68 • GZMB • ITGAM • BTLA • FOXP3 • MRC1 • ISG20","pipe":"","alterations":" ","tags":["PD-L1 • CD20 • CD8 • PD-1 • LAG3 • CD276 • CTLA4 • PD-L2 • VTCN1 • HAVCR2 • IL2RA • CD163 • TIGIT • PTPRC • NCAM1 • ICOS • CD14 • CD68 • GZMB • ITGAM • BTLA • FOXP3 • MRC1 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/08/2021","start_date":" 06/08/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-06-21"},{"id":"7751beea-ed0b-4a4d-8397-acffe8af0a14","acronym":"","url":"https://clinicaltrials.gov/study/NCT02432378","created_at":"2021-01-18T11:38:27.441Z","updated_at":"2024-07-02T16:35:00.114Z","phase":"Phase 1/2","brief_title":"Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines","source_id_and_acronym":"NCT02432378","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IFNG • CXCL10 • CXCL12 • CXCL9 • CD4 • IL10 • CXCL11 • CCL2 • ITGAM • FOXP3 • CCL22 • CCL3 • ITGAX","pipe":"","alterations":" ","tags":["IFNG • CXCL10 • CXCL12 • CXCL9 • CD4 • IL10 • CXCL11 • CCL2 • ITGAM • FOXP3 • CCL22 • CCL3 • ITGAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral"],"overall_status":"Suspended","enrollment":" Enrollment 25","initiation":"Initiation: 09/04/2015","start_date":" 09/04/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-05-30"},{"id":"dd45a77d-d5a4-4150-b58b-a6b91ace8084","acronym":"","url":"https://clinicaltrials.gov/study/NCT04513028","created_at":"2021-01-18T21:37:49.532Z","updated_at":"2024-07-02T16:35:01.212Z","phase":"","brief_title":"Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma","source_id_and_acronym":"NCT04513028","lead_sponsor":"Kelly McMasters","biomarkers":" IFNG • TNFA • PTPRC • ITGAM","pipe":" | ","alterations":" IFNG expression","tags":["IFNG • TNFA • PTPRC • ITGAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IFNG expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/03/2020","start_date":" 11/03/2020","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-05-24"},{"id":"46a5415c-22f8-4ee5-9a6c-fe01bd492c0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06387082","created_at":"2024-04-26T14:50:27.501Z","updated_at":"2024-07-02T16:35:07.392Z","phase":"Phase 1","brief_title":"A Clinical Study of HMPL-506 in Patients With Hematological Malignancies","source_id_and_acronym":"NCT06387082","lead_sponsor":"Hutchmed","biomarkers":" HOXA9 • ITGAM","pipe":"","alterations":" ","tags":["HOXA9 • ITGAM"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 98","initiation":"Initiation: 05/09/2024","start_date":" 05/09/2024","primary_txt":" Primary completion: 10/08/2027","primary_completion_date":" 10/08/2027","study_txt":" Completion: 12/08/2027","study_completion_date":" 12/08/2027","last_update_posted":"2024-04-26"},{"id":"cb11cd54-0bac-4f20-bf14-95c5e18524bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04187703","created_at":"2022-04-24T09:01:41.679Z","updated_at":"2024-07-02T16:35:15.464Z","phase":"Phase 1","brief_title":"5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies","source_id_and_acronym":"NCT04187703","lead_sponsor":"Benjamin Tomlinson","biomarkers":" ABL1 • BCR • CD14 • DCK • DNMT1 • ITGAM • NT5C","pipe":" | ","alterations":" Chr del(5q)","tags":["ABL1 • BCR • CD14 • DCK • DNMT1 • ITGAM • NT5C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(5q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • decitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/16/2020","start_date":" 11/16/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-03-11"},{"id":"e55830f0-b06e-4c54-bab4-91b6f117fa14","acronym":"","url":"https://clinicaltrials.gov/study/NCT04582487","created_at":"2021-01-18T21:51:58.830Z","updated_at":"2024-07-02T16:35:20.351Z","phase":"","brief_title":"Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL","source_id_and_acronym":"NCT04582487","lead_sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","biomarkers":" KIT • CD8 • CD33 • CD34 • CD5 • ITGAM • ANPEP","pipe":"","alterations":" ","tags":["KIT • CD8 • CD33 • CD34 • CD5 • ITGAM • ANPEP"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 05/19/2021","start_date":" 05/19/2021","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2024-02-07"},{"id":"d3399d53-3142-4fb8-8731-3da5f0cf0026","acronym":"TITAN-RCC","url":"https://clinicaltrials.gov/study/NCT02917772","created_at":"2021-08-04T19:53:08.805Z","updated_at":"2025-02-25T14:36:42.250Z","phase":"Phase 2","brief_title":"Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma","source_id_and_acronym":"NCT02917772 - TITAN-RCC","lead_sponsor":"AIO-Studien-gGmbH","biomarkers":" CD8 • PD-1 • PD-L2 • IL2RA • CD69 • ICOS • IL10 • CD14 • CD27 • LAMP1 • ITGAM • FAS • FOXP3 • IL17A • IL3RA • ITGAX • B3GAT1 • CD1C • CLEC4C","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • PD-L2 • IL2RA • CD69 • ICOS • IL10 • CD14 • CD27 • LAMP1 • ITGAM • FAS • FOXP3 • IL17A • IL3RA • ITGAX • B3GAT1 • CD1C • CLEC4C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Completed","enrollment":" Enrollment 200","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 10/01/2022","study_completion_date":" 10/01/2022","last_update_posted":"2022-10-06"},{"id":"dcd072e3-9fd1-4a14-9cf9-d662805f13a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01668849","created_at":"2021-01-18T07:13:06.579Z","updated_at":"2024-07-02T16:36:05.856Z","phase":"Phase 1","brief_title":"Edible Plant Exosome Ability to Prevent Oral Mucositis Associated With Chemoradiation Treatment of Head and Neck Cancer","source_id_and_acronym":"NCT01668849","lead_sponsor":"University of Louisville","biomarkers":" CD8 • ITGAM • ITGAX","pipe":"","alterations":" ","tags":["CD8 • ITGAM • ITGAX"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 08/02/2012","start_date":" 08/02/2012","primary_txt":" Primary completion: 05/25/2022","primary_completion_date":" 05/25/2022","study_txt":" Completion: 06/03/2022","study_completion_date":" 06/03/2022","last_update_posted":"2022-08-09"},{"id":"bb63a75a-a14f-4835-81aa-e71fcefe0493","acronym":"","url":"https://clinicaltrials.gov/study/NCT00682032","created_at":"2021-01-18T02:32:57.777Z","updated_at":"2024-07-02T16:36:10.841Z","phase":"","brief_title":"The Effect of Beta-glucan in Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT00682032","lead_sponsor":"University of Louisville","biomarkers":" ITGAM","pipe":"","alterations":" ","tags":["ITGAM"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 10/01/2008","start_date":" 10/01/2008","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2022-05-06"},{"id":"a9a4b065-a72c-4e31-861d-bbef6a0e8d93","acronym":"PEOPLE","url":"https://clinicaltrials.gov/study/NCT03447678","created_at":"2021-01-18T16:59:58.507Z","updated_at":"2024-07-02T16:36:29.303Z","phase":"Phase 2","brief_title":"Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.","source_id_and_acronym":"NCT03447678 - PEOPLE","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" EGFR • PD-L1 • ALK • CD8 • LAG3 • HAVCR2 • CD33 • TIGIT • GZMB • ITGAM • FOXP3","pipe":" | ","alterations":" PD-L1 expression • PD-L1 underexpression • PD-1 expression • ALK translocation • HAVCR2 expression • PD-L1-L • FOXP3 expression","tags":["EGFR • PD-L1 • ALK • CD8 • LAG3 • HAVCR2 • CD33 • TIGIT • GZMB • ITGAM • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 underexpression • PD-1 expression • ALK translocation • HAVCR2 expression • PD-L1-L • FOXP3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 05/23/2018","start_date":" 05/23/2018","primary_txt":" Primary completion: 05/31/2022","primary_completion_date":" 05/31/2022","study_txt":" Completion: 05/31/2022","study_completion_date":" 05/31/2022","last_update_posted":"2021-06-09"},{"id":"dcdad3d6-48f2-4297-8c2d-3913160f5e47","acronym":"CCB-RT","url":"https://clinicaltrials.gov/study/NCT04002570","created_at":"2021-01-18T19:40:19.011Z","updated_at":"2024-07-02T16:36:31.169Z","phase":"","brief_title":"Adjuvant Radiotherapy on Circulating Cells in Breast Cancer Patients","source_id_and_acronym":"NCT04002570 - CCB-RT","lead_sponsor":"Clinica Luganese Moncucco","biomarkers":" ITGAM","pipe":"","alterations":" ","tags":["ITGAM"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 10/25/2015","start_date":" 10/25/2015","primary_txt":" Primary completion: 09/15/2020","primary_completion_date":" 09/15/2020","study_txt":" Completion: 12/30/2020","study_completion_date":" 12/30/2020","last_update_posted":"2021-04-27"},{"id":"1060c7ca-0db7-45ed-babc-f64f37892f87","acronym":"","url":"https://clinicaltrials.gov/study/NCT00905060","created_at":"2021-03-24T18:52:25.085Z","updated_at":"2024-07-02T16:36:32.909Z","phase":"Phase 2","brief_title":"HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM","source_id_and_acronym":"NCT00905060","lead_sponsor":"University of California, San Francisco","biomarkers":" PD-L1 • PTPRC • ITGAM","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • PTPRC • ITGAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Oncophage (Heat Shock Protein Peptide Complex-96)"],"overall_status":"Completed","enrollment":" Enrollment 70","initiation":"Initiation: 06/29/2009","start_date":" 06/29/2009","primary_txt":" Primary completion: 06/03/2014","primary_completion_date":" 06/03/2014","study_txt":" Completion: 06/03/2014","study_completion_date":" 06/03/2014","last_update_posted":"2021-03-24"},{"id":"66ef3214-4b89-457d-8aec-3ac1952dab69","acronym":"","url":"https://clinicaltrials.gov/study/NCT03486119","created_at":"2021-01-18T17:10:17.329Z","updated_at":"2024-07-02T16:36:39.983Z","phase":"","brief_title":"A Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy in NSCLC Patients","source_id_and_acronym":"NCT03486119","lead_sponsor":"Yonsei University","biomarkers":" PD-L1 • CD8 • PD-1 • LAG3 • IL2RA • TIGIT • IL7R • NCAM1 • S100A8 • HMGB1 • ITGAM • FOXP3 • ISG20","pipe":"","alterations":" ","tags":["PD-L1 • CD8 • PD-1 • LAG3 • IL2RA • TIGIT • IL7R • NCAM1 • S100A8 • HMGB1 • ITGAM • FOXP3 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 02/05/2018","start_date":" 02/05/2018","primary_txt":" Primary completion: 07/07/2020","primary_completion_date":" 07/07/2020","study_txt":" Completion: 07/07/2020","study_completion_date":" 07/07/2020","last_update_posted":"2020-10-19"},{"id":"2f9fa5a1-f8a1-4926-9315-c7558aef01b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04446130","created_at":"2021-01-18T21:23:46.117Z","updated_at":"2024-07-02T16:36:43.887Z","phase":"Phase 3","brief_title":"Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients","source_id_and_acronym":"NCT04446130","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" KIT • CD33 • CD34 • ITGAM • ANPEP","pipe":"","alterations":" ","tags":["KIT • CD33 • CD34 • ITGAM • ANPEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • decitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/01/2019","start_date":" 01/01/2019","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2020-06-24"},{"id":"1d6a0df2-89da-4e82-835c-bf4a019494be","acronym":"MechLungCa","url":"https://clinicaltrials.gov/study/NCT01710319","created_at":"2021-01-18T07:27:06.743Z","updated_at":"2024-07-02T16:37:10.964Z","phase":"","brief_title":"Mechanisms of Immunosurveillance for Lung Cancer","source_id_and_acronym":"NCT01710319 - MechLungCa","lead_sponsor":"Washington University School of Medicine","biomarkers":" PTPRC • ITGAM","pipe":"","alterations":" ","tags":["PTPRC • ITGAM"],"overall_status":"Completed","enrollment":" Enrollment 119","initiation":"Initiation: 09/01/2012","start_date":" 09/01/2012","primary_txt":" Primary completion: 07/07/2016","primary_completion_date":" 07/07/2016","study_txt":" Completion: 07/07/2016","study_completion_date":" 07/07/2016","last_update_posted":"2018-05-07"},{"id":"971629cb-29bd-45f4-97f0-1bc2f19d8868","acronym":"","url":"https://clinicaltrials.gov/study/NCT03283228","created_at":"2021-01-18T16:13:07.367Z","updated_at":"2024-07-02T16:37:17.937Z","phase":"","brief_title":"Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia","source_id_and_acronym":"NCT03283228","lead_sponsor":"Assiut University","biomarkers":" NCAM1 • ITGAM","pipe":"","alterations":" ","tags":["NCAM1 • ITGAM"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 12/01/2017","start_date":" 12/01/2017","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 10/01/2019","study_completion_date":" 10/01/2019","last_update_posted":"2017-09-14"},{"id":"5ba9b1be-cf4a-4b86-9279-5b70eda2c3e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00500058","created_at":"2021-01-18T01:47:34.825Z","updated_at":"2024-07-02T16:37:19.575Z","phase":"Phase 1","brief_title":"A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18","source_id_and_acronym":"NCT00500058","lead_sponsor":"GlaxoSmithKline","biomarkers":" CD20 • CD8 • IFNG • IL2RA • PTPRC • CD69 • FASLG • IL7R • NCAM1 • CD14 • CSF2 • ITGAM • FOXP3","pipe":"","alterations":" ","tags":["CD20 • CD8 • IFNG • IL2RA • PTPRC • CD69 • FASLG • IL7R • NCAM1 • CD14 • CSF2 • ITGAM • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • iboctadekin (SB-485232)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 07/31/2007","start_date":" 07/31/2007","primary_txt":" Primary completion: 03/04/2010","primary_completion_date":" 03/04/2010","study_txt":" Completion: 03/04/2010","study_completion_date":" 03/04/2010","last_update_posted":"2017-07-26"},{"id":"a2867969-e1e7-49b1-b317-607dc3c5c300","acronym":"","url":"https://clinicaltrials.gov/study/NCT03214718","created_at":"2021-01-18T15:51:49.866Z","updated_at":"2024-07-02T16:37:20.072Z","phase":"","brief_title":"Myeloid Derived Suppressor Cells and Chronic Myeloid Leukemia","source_id_and_acronym":"NCT03214718","lead_sponsor":"Assiut University","biomarkers":" ABL1 • BCR • CD33 • CD14 • ITGAM","pipe":" | ","alterations":" M-MDSCs","tags":["ABL1 • BCR • CD33 • CD14 • ITGAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e M-MDSCs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • nilotinib"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 08/05/2017","start_date":" 08/05/2017","primary_txt":" Primary completion: 08/05/2019","primary_completion_date":" 08/05/2019","study_txt":" Completion: 08/05/2019","study_completion_date":" 08/05/2019","last_update_posted":"2017-07-11"},{"id":"24dd0f83-5501-426c-b044-d1a1395f1d4b","acronym":"IMAGE","url":"https://clinicaltrials.gov/study/NCT02176447","created_at":"2021-01-18T10:08:36.865Z","updated_at":"2024-07-02T16:37:28.245Z","phase":"","brief_title":"Age-related Changes in the Immune System and Their Impact on Elderly Breast Cancer","source_id_and_acronym":"NCT02176447 - IMAGE","lead_sponsor":"Universitaire Ziekenhuizen Leuven","biomarkers":" HER-2 • ER • CD20 • CDKN2A • CD123 • NCAM1 • CD14 • ITGAM • IL3RA • ITGAX","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER • CD20 • CDKN2A • CD123 • NCAM1 • CD14 • ITGAM • IL3RA • ITGAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":"","study_completion_date":"","last_update_posted":"2016-10-25"}]